-
Putting Huntington’s disease medications to the test: results from the Neuro-HD trial
Latest News
-
HDBuzz Is Officially Independent: What This Means, and Why It Matters
We’re entering a new chapter. HDBuzz is now an independent organisation, strengthening our ability to report clearly, critically, and responsibly on HD research.
-
Huntington's disease therapeutics conference 2019 – Day 3
New insights into the huntingtin protein, and further progress in turning genetic quirks that modify the course of HD into treatments, on the final day of the therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 2
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
-
Huntington's disease therapeutics conference 2019 – Day 1
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Huntington's disease goes viral as UniQure inches ahead in gene therapy race
FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
HDSA FAQ on the Roche/Genentech RG6042 program
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
-
Kids sometimes get Huntington’s disease too
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
-
Roche announces details of its 'pivotal' huntingtin-lowering study
The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
HDBuzz Enrolls in Enroll-HD
As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here.
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
